Optimizing Lead Therapeutic Compounds Against Infectious Diseases

Information

• Research Project
• 9352962

• ApplicationId

  9352962

• Core Project Number

  N01AI000000

• Full Project Number

  272201500011C-2-0-2

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  6/30/2015 - 9 years ago

• Project End Date

  5/15/2017 - 7 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2016

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• KINETA, INC.

To support the advancement of promising lead therapeutics to the clinical drug candidate stage for the treatment of infectious diseases. Activities that may be supported include medicinal chemistry and preclinical in vitro and in vivo testing of a lead compound series in order to produce profiles of their efficacy, synthetic feasibility, stability, and toxicity, which will be used to identify a novel small molecule drug candidate for future clinical development.

IC Name

• Activity

  N01

• Administering IC

  AI

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  641709

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  855

• Ed Inst. Type

• Funding ICs

  NIAID:641709\

• Funding Mechanism

  Non SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  KINETA, INC.

• Organization Department

• Organization DUNS

  809832558

• Organization City

  SEATTLE

• Organization State

  WA

• Organization Country

  UNITED STATES

• Organization Zip Code

  981095230

• Organization District

  UNITED STATES